Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation

Bone Marrow Transplantation volume 36, pages 793–796 (2005)Cite this article

Summary:

Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma (MM). We evaluated 126 MM patients for t(4;14) or t(11;14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. We demonstrate the significance of genetic-based risk classification that clearly segregate patients into low (no genetic abnormalities or only t(11;14)), intermediate (any one of the genetic abnormalities other than t(11;14)) and high-risk groups (any two or more of the genetic abnormalities other than t(11;14)). High-risk patients do not benefit from stem cell transplant and should be offered alternative therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Avet-Loiseau H, Brigaudeau C, Morineau N et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 1999; 24: 9–15.

    Article  CAS  Google Scholar 

  2. Bergsagel PL, Kuehl WM . Chromosome translocations in multiple myeloma. Oncogene 2002; 20: 5611–5622.

    Article  Google Scholar 

  3. Moreau P, Facon T, Leleu X et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–1583.

    Article  CAS  Google Scholar 

  4. Chang H, Sloan S, Li D et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64–68.

    Article  Google Scholar 

  5. Chang H, Qi XY, Yi QL et al. P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105: 358–360.

    Article  CAS  Google Scholar 

  6. Chang H, Li D, Zhuang L et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma 2004; 45: 965–969.

    Article  CAS  Google Scholar 

  7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trail of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myeloma. N Engl J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  8. Child JA, Morgan GJ, Davies FE et al. Medical research council adult leukaemia working party. High-dose chemotherapy and hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  Google Scholar 

  9. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32.

    Article  CAS  Google Scholar 

  10. Avet-Loiseau H, Facon T, Grobois B et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185–2191.

    Article  CAS  Google Scholar 

  11. Fonseca R, Oken MM, Greipp PR, Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2002; 98: 1271–1272.

    Article  Google Scholar 

  12. Fonseca R, Blood E, Rue M et al. Clinical biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.

    Article  CAS  Google Scholar 

  13. Konigsberg R, Zojer N, Ackermann J et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000; 18: 804–812.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by a grant from the Leukemia Research Fund of Canada, Canadian Institute for Health Research and National Cancer Institute of Canada.

Author information

Authors and Affiliations

  1. Department of Laboratory Hematology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada

    H Chang & X Y Qi

  2. Department of Laboratory Medicine and Pathobiology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada

    H Chang & X Y Qi

  3. Department of Medical Oncology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada

    S Samiee, C Chen, S Trudel, J Mikhael, D Reece & A K Stewart

  4. Department of Biostatistics, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada

    Q-L Yi

Authors
  1. H Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X Y Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Samiee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Q-L Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Trudel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Mikhael
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Reece
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A K Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Chang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, H., Qi, X., Samiee, S. et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 36, 793–796 (2005). https://doi.org/10.1038/sj.bmt.1705131

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705131

Keywords

This article is cited by

Search

Advanced search

Quick links